Firefly luciferase offers superior performance to AkaLuc for tracking the fate of administered cell therapies.

Francesco Amadeo Antonius Plagge Anitta Chacko Bettina WilmVivien HansonNeill J Liptrott Patricia Murray Arthur Taylor

Published in: European journal of nuclear medicine and molecular imaging (2021)

We conclude that there is no advantage in using the AkaBLI system to track the biodistribution of systemically administered cell-based regenerative medicine therapies in vivo.

Keyphrases

single cell
cell therapy
stem cells
mesenchymal stem cells